1型糖尿病女性的血糖控制与子痫前期风险:一项全国性队列研究
该研究基于瑞典全国登记数据(2003–2019年单胎妊娠,共1689301例,其中1型糖尿病4429例),发现1型糖尿病女性子痫前期发生率为16.8%,显著高于无糖尿病女性的2.9%(校正RR 4.7,95%CI 4.4-5.0),且风险随围受孕HbA1c升高呈剂量反应关系。
要点
- 1型糖尿病女性子痫前期风险是无糖尿病女性的约4.7倍(校正RR 4.7,95%CI 4.4-5.0)。
- 围受孕HbA1c从<48 mmol/mol升至≥76 mmol/mol,子痫前期发生率从11.6%升至23.3%。
- 与无糖尿病女性相比,1型糖尿病女性早产子痫前期风险更高:早期早产校正RR 7.2,晚期早产校正RR 9.9,足月子痫前期校正RR 3.5。
核心结论
- 1型糖尿病女性子痫前期风险更高,且风险随围受孕血糖控制变差呈剂量反应性增加。
研究设计与样本
- 基于人群的全国性队列研究,使用瑞典国家糖尿病登记及其他健康登记数据,纳入2003–2019年单胎妊娠共1689301例,其中1型糖尿病4429例。
- 主要暴露为孕前诊断的1型糖尿病(首次诊断在受孕后≤91天且受孕前后±90天内有至少1次HbA1c值),按最近一次HbA1c测量值(mmol/mol)分为<48、48-61、62-75、≥76四组;未暴露组为无任何糖尿病诊断(受孕后≤91天)的女性。
主要发现
- 1型糖尿病女性子痫前期发生率为16.8%,无糖尿病女性为2.9%(校正RR 4.7,95%CI 4.4-5.0)。
- 围受孕HbA1c从<48 mmol/mol升至≥76 mmol/mol时,子痫前期发生率从11.6%升至23.3%。
- 与未暴露组相比,1型糖尿病女性子痫前期风险随HbA1c升高而增加:<48 mmol/mol校正RR 3.4(2.9-4.0);48-61 mmol/mol校正RR 4.6(4.2-5.1);62-75 mmol/mol校正RR 5.7(5.0-6.5);≥76 mmol/mol校正RR 6.3(95%CI 5.3-7.7)。
- 与未暴露组相比,1型糖尿病女性足月子痫前期校正RR为3.5(3.1-3.9),早期早产子痫前期校正RR为7.2(6.1-8.5),晚期早产子痫前期校正RR为9.9(8.8-11.1)。
关键数值与推荐
- 子痫前期使用ICD编码定义,并按分娩时完成孕周分类:早期早产子痫前期(<34+0周)、晚期早产子痫前期(34+0至36+6周)、足月子痫前期(≥37+0周)。
- 围受孕血糖控制按最近一次HbA1c测量值(mmol/mol)分类:<48、48-61、62-75、≥76。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: No large-scale studies exist investigating glycaemic control around conception and preeclampsia risk. DESIGN: Population-based nationwide cohort study using the National Diabetes Register and other health registers. SETTING: Sweden. POPULATION: Singleton pregnancies between 2003 and 2019 (N = 1 689 301); 4429 with type 1 diabetes (T1DM) and 1 684 872 without. METHODS: The main exposure was having a pre-gestational diagnosis of T1DM (first diagnosis anytime ≤ 91 days after conception and ≥ 1value of glycated haemoglobin (HbA1c) within ±90 days from conception). Peri-conceptional glycaemic control was categorised using the most recent HbA1c measurement (mmol/mol: < 48; 48-61; 62-75; ≥ 76). Unexposed were women without any diabetes diagnosis (≤ 91 days after conception). MAIN OUTCOME MEASURES: Preeclampsia was defined using ICD codes and further categorised according to completed gestational weeks at delivery with preeclampsia diagnosis: early preterm preeclampsia (< 34 + 0), late preterm preeclampsia (34 + 0 to 36 + 6), or term preeclampsia (≥ 37 + 0). RESULTS: 16.8% of women with T1DM developed preeclampsia, compared to 2.9% of women without diabetes (adjusted RR [aRR] 4.7, 95% CI 4.4-5.0). Preeclampsia risk increased with peri-conceptional HbA1c, from 11.6% in women with HbA1c < 48 mmol/mol to 23.3% in women with HbA1c ≥ 76 mmol/mol. Compared to unexposed women, there was a dose-response relationship between HbA1c and preeclampsia in women with T1DM (HbA1c < 48 mmol/mol aRR 3.4 (2.9-4.0); HbA1c 48-61 mmol/mol aRR 4.6 (4.2-5.1); HbA1c 62-75 mmol/mol aRR 5.7 (5.0-6.5): HbA1c ≥ 76 mmol/mol aRR 6.3 (CI 5.3-7.7)). Compared to unexposed women, the aRR of term preeclampsia was 3.5 times higher (3.1-3.9) in women with T1DM, while the aRR was much higher for early preterm preeclampsia (aRR 7.2: 6.1-8.5) and late preterm preeclampsia (aRR 9.9: 8.8-11.1). CONCLUSIONS: Women with T1DM had a higher risk of preeclampsia, which increased in a dose-response manner with poorer peri-conceptional glycaemic control.
引用
- Holowko N, Roos N, Pasternak B, et al. Glycaemic Control in Women With Type 1 Diabetes and Preeclampsia Risk: A Nationwide Cohort Study. BJOG. 2025. PMID: 40856153. doi:10.1111/1471-0528.18339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。